Zacks.com on MSN9d
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial CancerGSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus ...
The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...
GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...
Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...
The European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for ...
GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of ...
GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line ...
La Comisión Europea ha aprobado el fármaco 'JEMPERLI' (dostarlimab), de GSK, en combinación con la quimioterapia estándar ...
European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...
London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback